Efficacy of antitumour colon cancer cell vaccine modified by Escherichia coli cytosine deaminase gene.
- Author:
Li-zong SHEN
1
;
Jian-hua WANG
;
Hai-quan WANG
;
Yi-bing HUA
;
Wen-xi WU
Author Information
- Publication Type:Journal Article
- MeSH: Amino Acid Motifs; Animals; Cancer Vaccines; therapeutic use; Cell Line, Tumor; Colonic Neoplasms; therapy; Cytosine Deaminase; genetics; Escherichia coli; enzymology; genetics; Escherichia coli Proteins; genetics; Humans; Mice; Mice, Inbred BALB C
- From: Chinese Journal of Gastrointestinal Surgery 2006;9(5):425-428
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo evaluate the efficacy of antitumour colon cancer cell vaccine modified by escherichia coli cytosine deaminase (EC-CD).
METHODSMouse colon cancer cell vaccine CT26/CD was established by gene modification using retrovirus plasmid pLCDSN. Its tumorigenicity and effect on liver metastasis model established with wild-type colon cancer were evaluated.
RESULTSCT26/CD was established successfully and proliferated in medium containing 0.6 g/L G418 stably. EC-CD gene expression on these mutant cells was confirmed by RT-PCR. These mutant cells were more sensitive to 5-fluorocytosine (5-FC) compared with the wild-type ones (P=0.000), and presented excellent bystander effect. CT26/CD had the same tumorigenicity as its parental cells (P=0.892). CT26/CD, combined with the prodrug 5-FC, could inhibit tumor progress and live metastasis, and prolonged the survival of the liver metastasis model animals (P=0.000).
CONCLUSIONThe colon cancer cell vaccine modified by EC-CD presented anti-tumor effect in vivo, when treated with the prodrug.
